P/B
4,8
Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
$1.1B
Market Cap • 9/15/2026
2014
(12 years)
Founded
2016
(10 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,6
EPS
—
Market Cap
Market Cap
1,1B
EV
874,9M
EV/Revenue
0
EV/EBITDA
-15,4
EV/EBIT
-15,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-17,6%
Total Yield
-17,6%
Payout
0%
Retained Earnings
-443,9M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
596,6%
Capex/OCF
-1,6%
SBC/OCF
—
% PPE
0,6%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
6%
CAGR Net Income 5Y
56,4%
CAGR EPS 5Y
82,7%
CAGR OCF 5Y
3,6%
Leverage
N.D./EBITDA
3,8
Debt/Equity
0%
Current Ratio
16,2
Quick Ratio
15,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!